@article{b9424c25d45f43c0ad51482e77f405af,
title = "Japanese Clinical Practice Guidelines for Management of Clostridioides (Clostridium) difficile infection",
author = "Hiroyuki Kunishima and Hiroki Ohge and Hiromichi Suzuki and Atsushi Nakamura and Kazuaki Matsumoto and Hiroshige Mikamo and Nobuaki Mori and Yoshitomo Morinaga and Katsunori Yanagihara and Yuka Yamagishi and Sadako Yoshizawa",
note = "Funding Information: Hiroshige Mikamo received scholarship funds from Asahi Kasei Pharma Corp., Astellas Pharma Inc., MSD K.K., Eneforest Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Takeda Pharmaceutical Co., Ltd., Toyama Chemical Co., Ltd., Pfizer Japan Inc., FUJIFILM Pharma Co., Ltd., Hologic Japan Inc., Miyarisan Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd. Funding Information: Formulation of the present guidelines was entirely funded by the Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Funding Information: Yoshitomo Morinaga received scholarship funds from SRL, Inc., Sumitomo Dainippon Pharma Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Toyama Chemical Co., Ltd., Astellas Pharma Inc., Mitsui Chemicals, Inc., and MSD K.K. Funding Information: Katsunori Yanagihara received scholarship funds from SRL, Inc., Sumitomo Dainippon Pharma Co., Ltd., Pfizer Japan Inc., Daiichi Sankyo Co., Ltd., Toyama Chemical Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Astellas Pharma Inc., Mitsui Chemicals, Inc., MSD K.K., Shionogi & Co., Ltd., Nippon Becton Dickinson Co., Ltd., Hitachi High Technologies Co., Ltd., and Beckman Coulter K.K. Funding Information: Yuka Yamagishi received scholarship funds from MSD K.K., Asahi Kasei Pharma Corp., Astellas Pharma Inc., Eneforest Co., Ltd., Shionogi & Co., Ltd., Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Toyama Chemical Co., Ltd., Pfizer Japan Inc., FUJIFILM Pharma Co., Ltd., Miyarisan Pharmaceutical Co., Ltd., and Meiji Seika Pharma Co., Ltd. Funding Information: Hiroki Ohge received scholarship funds from Daiichi Sankyo Co., Ltd., Taisho Toyama Pharmaceutical Co., Ltd., and Shionogi & Co., Ltd. ",
year = "2022",
month = aug,
doi = "10.1016/j.jiac.2021.12.011",
language = "English",
volume = "28",
pages = "1045--1083",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "8",
}
